1. Home
  2. NZF vs TWST Comparison

NZF vs TWST Comparison

Compare NZF & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Municipal Credit Income Fund

NZF

Nuveen Municipal Credit Income Fund

HOLD

Current Price

$12.87

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Twist Bioscience Corporation

TWST

Twist Bioscience Corporation

HOLD

Current Price

$48.39

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NZF
TWST
Founded
N/A
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
3.0B
IPO Year
2001
2018

Fundamental Metrics

Financial Performance
Metric
NZF
TWST
Price
$12.87
$48.39
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$48.75
AVG Volume (30 Days)
645.5K
1.5M
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
N/A
$376,572,000.00
Revenue This Year
N/A
$18.89
Revenue Next Year
N/A
$15.28
P/E Ratio
N/A
N/A
Revenue Growth
N/A
20.32
52 Week Low
$10.98
$23.30
52 Week High
$13.02
$57.88

Technical Indicators

Market Signals
Indicator
NZF
TWST
Relative Strength Index (RSI) 60.82 57.00
Support Level $12.73 $46.96
Resistance Level $13.02 $57.88
Average True Range (ATR) 0.11 3.23
MACD 0.02 0.03
Stochastic Oscillator 75.41 42.26

Price Performance

Historical Comparison
NZF
TWST

About NZF Nuveen Municipal Credit Income Fund

Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

Share on Social Networks: